Back to top
more

Addus HomeCare (ADUS)

(Delayed Data from NSDQ)

$97.16 USD

97.16
112,773

+0.54 (0.56%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $97.24 +0.08 (0.08%) 6:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Elevance Health (ELV), CD&R to Unveil Primary Care Offering

by Zacks Equity Research

Elevance Health (ELV) forms an alliance with CD&R to enhance primary care delivery by making collective use of the partners' assets and subsequently, reduce overall costs of care.

Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?

by Zacks Equity Research

Here is how HCA Healthcare (HCA) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.

ADUS vs. USPH: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Acadia (ACHC) Buys CTCs to Boost Care Access in North Carolina

by Zacks Equity Research

Acadia Healthcare (ACHC) acquires three CTCs in the Raleigh, Greenville and Hillsborough regions of North Carolina, therefore increasing its CTC nationwide footprint and fetching improved revenues.

Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Masimo (MASI) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.

ADUS or USPH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Encompass Health (EHC) Up 42% in a Year: What Lies Ahead?

by Zacks Equity Research

Encompass Health (EHC) remains well-poised for growth on the back of sustained top-line growth, an expanding healthcare facility portfolio and robust cash-generating abilities.

DaVita Inc. (DVA) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Tenet Healthcare (THC) to Sell Hospitals to Refine Portfolio

by Zacks Equity Research

Tenet Healthcare (THC) enters an agreement with Adventist Health to divest two of THC's hospitals, and continue to make Conifer's revenue cycle management services available for the divested operations.

Is Addus HomeCare (ADUS) Stock a Solid Choice Right Now?

by Zacks Equity Research

Addus HomeCare (ADUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Addus HomeCare (ADUS) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Addus HomeCare (ADUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ADUS vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

ADUS vs. CHE: Which Stock Is the Better Value Option?

Addus HomeCare (ADUS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Addus HomeCare (ADUS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Countdown to Addus HomeCare (ADUS) Q4 Earnings: Wall Street Forecasts for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Addus HomeCare (ADUS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Debanjana Dey headshot

4 Stocks to Watch in a Resilient Outpatient Home Health Industry

by Debanjana Dey

The rising dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DVA, EHC, OPCH and ADUS are well-poised to gain.

Zacks Industry Outlook Highlights DaVita, Option Care Health, Addus HomeCare and Pennant

by Zacks Equity Research

DaVita, Option Care Health, Addus HomeCare and Pennant have been highlighted in this Industry Outlook article.

Debanjana Dey headshot

4 Stocks to Watch in an Evolving Outpatient Home Health Industry

by Debanjana Dey

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, OPCH, ADUS and PNTG are well-poised to gain.

ADUS or USPH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Wall Street Analysts Believe Addus HomeCare (ADUS) Could Rally 27.47%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 27.5% in Addus HomeCare (ADUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

UnitedHealth (UNH) Unit Makes Insulin More Affordable to Avail

by Zacks Equity Research

UnitedHealth Group's (UNH) sub-unit, Optum Rx, resorts to product shift within its formulary and makes the vital medication of insulin cost-effective, thereby boosting patients' access to it.

ADUS or USPH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Does Addus HomeCare (ADUS) Have the Potential to Rally 33.85% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 33.9% in Addus HomeCare (ADUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Addus HomeCare (ADUS) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 9.52% and 1.71%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad (BIO) Misses Q3 Earnings Estimates, Cuts 2023 View

by Zacks Equity Research

The deterioration in biopharma and early biotech customer spending and a challenging macroeconomic environment in China impact Bio-Rad's (BIO) Q3 performance.

Boston Scientific (BSX) Q3 Earnings Beat, Gross Margin Dips

by Zacks Equity Research

Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the third quarter.